- Charles River’s fourth-quarter revenue reached $1.00 billion, outperforming estimates despite a 1.1% year-over-year decrease. The market had anticipated $983.4 million.
- The Research Models & Services segment generated $204.3 million, reflecting a 4.3% increase year-over-year, slightly surpassing the estimated $203.3 million.
- Discovery & Safety Assessment revenue was $603.3 million, down 3.6% from the previous year, yet still higher than the market expectation of $574.3 million.
- In the Manufacturing Solutions category, revenue was $194.9 million, an increase of 1.6% year-over-year, although it fell short of the $207.6 million estimate.
- Adjusted Earnings Per Share (EPS) was reported at $2.66.
- Analyst ratings for Charles River include 4 buys, 13 holds, and 3 sells.
“`
A look at Charles River Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Charles River Laboratories International, Inc. plays a vital role in the pharmaceutical and biotechnology industry by providing research tools and support services for drug discovery and development. With a solid score of 3 in Value and Growth, the company is positioned well for long-term success in terms of its intrinsic worth and potential for expansion. While its Dividend score is lower at 1, indicating a lower payout to investors, Charles River Laboratories shows promise in terms of its resilience and momentum, scoring 2 in both categories. This suggests that despite challenges, the company has the capacity to adapt and grow steadily over time.
Overall, the Smartkarma Smart Scores paint a positive picture for Charles River Laboratories in the long run. With a focus on innovation and meeting the needs of its diverse customer base including pharmaceutical and biotechnology companies, hospitals, and academic institutions, the company appears to have a solid foundation for sustained growth. Investors looking for a company with strong value and growth prospects may find Charles River Laboratories an appealing long-term investment option.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
